Dr Reddy’s Laboratories has dipped nearly 3% to Rs 2,538, extending its previous day’s 4% fall, after the pharma major reported a 16% year on year (yoy) decline in consolidated net profit at Rs 482 crore for the quarter ended March 31, 2014 (Q4), due to lower sales growth, higher SG&A (selling, general and administrative) expenses. The company had registered a profit of Rs 571 crore in the same quarter year ago.
Net sales of the company in Q4, 2013-14 rose to Rs 3,481 crore from Rs 3,340 crore in the year-ago period.
The company said the SG&A expenses rose 18% yoy to Rs 1,031 crore for the fourth quarter of last fiscal, from Rs 872 crore in the year-ago period.
However, analyst at Angel Broking maintains buy recommendation on the stock with a price target of Rs 3,634.
The stock opened at Rs 2,600 and touched a low of Rs 2,525 on the NSE. A combined 595,000 shares changed hands on the counter so far on the NSE and BSE.
Net sales of the company in Q4, 2013-14 rose to Rs 3,481 crore from Rs 3,340 crore in the year-ago period.
The company said the SG&A expenses rose 18% yoy to Rs 1,031 crore for the fourth quarter of last fiscal, from Rs 872 crore in the year-ago period.
However, analyst at Angel Broking maintains buy recommendation on the stock with a price target of Rs 3,634.
The stock opened at Rs 2,600 and touched a low of Rs 2,525 on the NSE. A combined 595,000 shares changed hands on the counter so far on the NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%